Literature DB >> 8003648

Relationships between the severity of cirrhosis and haemodynamic values in patients with cirrhosis.

H C Meng1, H C Lin, Y T Tsai, F Y Lee, D M Liao, H C Hsia, W J Lin, T T Chang, C S Lay, S S Wang.   

Abstract

The relationship between the severity of cirrhosis and systemic and hepatic haemodynamic values was evaluated in 193 patients with cirrhosis, most of whom were diagnosed with post-necrotic cirrhosis. It was found that the hepatic venous pressure gradient and cardiac output in Pugh's A patients (13.6 +/- 4.8 mmHg and 6.2 +/- 1.6 L/min, mean +/- s.d.) were significantly lower than in both Pugh's B (16.8 +/- 4.3 mmHg and 7.3 +/- 2.1 L/min) and Pugh's C (18.8 +/- 5.5 mmHg and 7.4 +/- 2.3 L/min) patients (P < 0.01), respectively. In contrast, the systemic vascular resistance in Pugh's A patients (1232 +/- 369 dyn/s per cm5) was significantly higher than in both Pugh's B (1016 +/- 345 dyn/s per cm5) and Pugh's C (935 +/- 234 dyn/s per cm5) patients (P < 0.01), respectively. Additionally, not only was there a positive correlation found between Pugh's score and cardiac output and hepatic venous pressure gradient, but a negative correlation was found between Pugh's score and systemic vascular resistance. It was also confirmed that the degree of portal hypertension and the hyperdynamic circulation were more severe in patients with ascites than in those without ascites. However, there were no statistically significant differences in hepatic venous pressure gradient among patients with F1, F2 and F3 esophageal varices (15.7 +/- 4.0, 17.0 +/- 4.8 and 18.0 +/- 4.8 mmHg, respectively). It is concluded that in those patients with cirrhosis, the severity of cirrhosis is closely related to the degree of the hyperkinetic circulatory state and portal hypertension.

Entities:  

Mesh:

Year:  1994        PMID: 8003648     DOI: 10.1111/j.1440-1746.1994.tb01235.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

Review 1.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

2.  Scintigraphic evaluation of hepatic blood flow after intrahepatic portosystemic shunt (TIPS).

Authors:  J Menzel; O Schober; P Reimer; W Domschke
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Superior Mesenteric Arterial Flow Pattern is Associated with Major Adverse Events in Adults with Fontan Circulation.

Authors:  Makoto Mori; Kayoko Shioda; Robert W Elder; Maria A Pernetz; Fred H Rodriguez; Alicia Rangosch; Brian E Kogon; Wendy M Book
Journal:  Pediatr Cardiol       Date:  2016-03-31       Impact factor: 1.655

4.  Non-invasive Diagnosis of Oesophageal Varices Using Systemic Haemodynamic Measurements by Finometry: Comparison with Other Non-invasive Predictive Scores.

Authors:  Kara Rye; Gerri Mortimore; Andrew Austin; Jan Freeman
Journal:  J Clin Exp Hepatol       Date:  2016-05-13

5.  A quantitative study on vascular angiotensin II receptors in rats with portal hypertension.

Authors:  J Li; Z Dai; W Cui; Y Hu
Journal:  J Tongji Med Univ       Date:  1997

6.  Nitric oxide synthase activity in arterial tissues of cirrhotic rats.

Authors:  P Zhang; K Liang; J Lin; T Wang; L Du
Journal:  J Tongji Med Univ       Date:  1997

7.  Relationship of 24-hour ambulatory blood pressure and heart rate with markers of hepatic function in cirrhotic patients.

Authors:  Dimitris G Tzamouranis; Alexandra Alexopoulou; Spyros P Dourakis; George S Stergiou
Journal:  BMC Gastroenterol       Date:  2010-12-12       Impact factor: 3.067

8.  Towards noninvasive detection of oesophageal varices.

Authors:  Kara Rye; Robert Scott; Gerri Mortimore; Adam Lawson; Andrew Austin; Jan Freeman
Journal:  Int J Hepatol       Date:  2012-03-14

9.  Quantitative modeling of the physiology of ascites in portal hypertension.

Authors:  David G Levitt; Michael D Levitt
Journal:  BMC Gastroenterol       Date:  2012-03-27       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.